文献速递儿童呼吸儿童感染新生儿

帕利珠单抗治疗小婴儿RSV毛细支气管炎的随机试验

Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.
PubMed 文献 · Pediatrics · 2019-02-13

这项双盲随机对照试验纳入≤3月龄、因RSV阳性毛细支气管炎需住院的婴儿,比较单剂静脉帕利珠单抗(15 mg/kg)与安慰剂。

要点

  • ≤3月龄RSV毛细支气管炎住院婴儿中,单剂静脉帕利珠单抗未减少出院后3周再住院。
  • 帕利珠单抗组与安慰剂组至出院准备时间几何均值分别为29.5小时与30.2小时,无显著差异。
  • 该研究未报告安全问题,但帕利珠单抗不应用于RSV毛细支气管炎的常规治疗。

核心结论

  • 静脉帕利珠单抗对急性RSV阳性毛细支气管炎小婴儿既未见帮助也未见伤害。

研究设计与样本

  • 双盲随机对照试验,纳入≤3月龄因RSV阳性毛细支气管炎需住院的婴儿,随机接受单剂静脉帕利珠单抗15 mg/kg或安慰剂。
  • 共420例婴儿随机分组(中位年龄49天),417例接受治疗,413例完成随访。

主要发现

  • 至出院准备时间几何均值:帕利珠单抗组29.5小时,安慰剂组30.2小时(比值0.98;95%CI 0.81至1.20)。
  • 未报告安全问题。

关键数值与推荐

  • 主要疗效结局为出院后3周内需再住院。
  • 次要结局包括至出院准备时间、初始住院需PICU及3周随访内同病再访无需再住院。

临床怎么用

  • 不推荐将帕利珠单抗用于小婴儿急性RSV毛细支气管炎的治疗。
  • 帕利珠单抗仍仅推荐用于高风险婴儿RSV毛细支气管炎的预防,而非治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monoclonal antibody to respiratory syncytial virus (RSV; palivizumab) is recommend for prophylaxis of high-risk infants during bronchiolitis seasons but not for RSV bronchiolitis treatment. Our aim was to determine if palivizumab would be helpful in young infants with acute RSV bronchiolitis. METHODS: Eligible infants ≤3 months old presenting to the pediatric emergency service with RSV-positive bronchiolitis requiring inpatient admission underwent double-blind random assignment to single-dose intravenous palivizumab (15 mg/kg) or placebo. The primary efficacy outcome was the need for inpatient readmission in the 3 weeks after discharge. Secondary outcomes were time to readiness for hospital discharge, need for PICU on the initial admission, and need for revisit not requiring readmission for the same illness during 3-week follow-up. RESULTS: A total of 420 infants (median age 49 days) diagnosed with RSV bronchiolitis were randomly assigned; 417 received treatment, and 413 completed follow-up. Readmission during follow-up was needed for 23 (11%) patients on palivizumab and 19 (9.3%) patients in the placebo group (difference 1.8%; 95% confidence interval -4.4% to 7.7%; P = .51). Geometric mean time to readiness for discharge was 29.5 hours for the palivizumab group and 30.2 hours for the placebo group (ratio 0.98; 95% confidence interval 0.81 to 1.20). No safety issues were reported. CONCLUSIONS: Intravenous palivizumab did not appear to help or harm young infants with acute RSV-positive bronchiolitis.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Alansari K, Toaimah FH, Almatar DH, et al. Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial. Pediatrics. 2019. PMID: 30760509. doi:10.1542/peds.2018-2308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。